Oxford Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Oxford Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4,845	Closed	-$639K	–	824
2025 Q1	$639K	Buy	+4,845	New	+$604K	0.29%	93
2019 Q3	–	Sell	-11,581	Closed	-$150K	–	1986
2019 Q2	$150K	Buy	+11,581	New	+$149K	﹤0.01%	1584
2018 Q2	–	Sell	-52,363	Closed	-$1.1M	–	1968
2018 Q1	$1.1M	Sell	52,363 -15,093	-22%	-$294K	0.02%	898
2017 Q4	$1.02M	Sell	67,456 -6,581	-9%	-$102K	0.02%	921
2017 Q3	$1.14M	Buy	+74,037	New	+$1.09M	0.02%	890
2017 Q1	–	Sell	-48,254	Closed	-$728K	–	1485
2016 Q4	$728K	Sell	48,254 -19,400	-29%	-$274K	0.03%	533
2016 Q3	$1.03M	Buy	+67,654	New	+$2.74M	0.03%	512
2016 Q2	–	Sell	-23,239	Closed	-$646K	–	889
2016 Q1	$646K	Sell	23,239 -13,368	-37%	-$446K	0.02%	570
2015 Q4	$1.99M	Buy	+36,607	New	+$1.85M	0.05%	398

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Oxford Asset Management's ITCI Position: Q2 2025 in Review

Oxford Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 4,845 shares — an estimated $639K sold.

Oxford Asset Management first reported a position in ITCI in Q4 2015 and held it in 9 quarters. The position peaked at $1.99M in Q4 2015. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Oxford Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Oxford Asset Management sold 4,845 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $639K.
Oxford Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2015 and held it in 9 quarters.
Oxford Asset Management's Intra-Cellular Therapies Inc. position peaked at $1.99M in Q4 2015.
3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Oxford Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.